Lonza and Cellectis Bioresearch sign r&d agreement
Cellectis to use meganucleases to deactivate the glutamine synthetase (GS) in Lonza\'s CHOK1SV
Swiss drug ingredients manufacturer Lonza has signed an agreement with Cellectis Bioresearch, the French genome customisation specialist for the development and commercialisation of a bioengineered cell line.
Cellectis Bioresearch will use its meganucleases to deactivate the glutamine synthetase (GS) in CHOK1SV, Lonza’s proprietary host cell line.
Cellectis Bioresearch specialises in the commercialisation of genome customisation tools using meganucleases, which are molecular scissors that can be directed to a single specific site in the genome of a cell, thereby allowing a range of precise genome modifications, including targeted gene integration, gene knock-out and modulation of gene function.
‘Lonza’s ability to master production of the highest quality cell lines makes the company a perfect partner for the application of our meganuclease technology,’ said Marc Le Bozec, ceo of Cellectis Bioresearch.
John Birch, CSO of Lonza Biopharmaceuticals, added: ‘This collaboration makes sense and will enhance our long-standing and successful GS technology.’
Lonza’s GS System uses selection via glutamine metabolism to generate high-yielding and stable producing cell lines.
